CD-8 Immunohistochemistry at Lahore PCR Lab

CD-8 Immunohistochemistry at Lahore PCR Lab

CD-8 Immunohistochemistry (IHC) is a highly specialized pathology investigation performed to detect and visualize CD8-positive cytotoxic T-lymphocytes within tissue samples. At Lahore PCR Lab in Lahore, Pakistan, this advanced diagnostic test plays a critical role in oncological pathology, immunology, and infectious disease diagnostics. CD8 is a cell-surface glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). It is predominantly expressed on cytotoxic T-cells, which are essential components of the adaptive immune system responsible for destroying virus-infected cells and tumor cells. By utilizing specific monoclonal antibodies directed against the CD8 antigen, our expert pathologists can identify the spatial distribution, density, and localization of these immune cells within a tissue microenvironment.

The clinical utility of CD-8 Immunohistochemistry is vast. In modern oncology, the presence and distribution of tumor-infiltrating lymphocytes (TILs) are key prognostic indicators. High density of CD8+ T-cells within the tumor core or invasive margin is often associated with a favorable prognosis and a better response to immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Conversely, a lack of CD8+ T-cell infiltration, often referred to as an ‘immune-cold’ tumor, may suggest resistance to certain immunotherapies. Beyond oncology, CD-8 IHC is instrumental in diagnosing T-cell lymphoproliferative disorders, monitoring organ transplant rejection, and evaluating inflammatory or autoimmune diseases. Lahore PCR Lab utilizes state-of-the-art automated staining platforms and high-affinity antibodies to ensure maximum sensitivity, specificity, and reproducibility for every patient sample.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-8 Immunohistochemistry is performed on tissue specimens rather than directly on the patient, preparation is centered around the initial tissue collection procedure (biopsy or surgical resection) rather than the laboratory staining process itself. Patients should observe the following guidelines:

• Consult with the referring surgeon or clinician regarding specific preparation requirements for the biopsy or surgical procedure (e.g., fasting, stopping blood thinners).
• Ensure that all relevant clinical history, previous pathology reports, and imaging results are provided to Lahore PCR Lab along with the tissue specimen.
• If submitting a pre-existing formalin-fixed paraffin-embedded (FFPE) tissue block or unstained slides from another facility, verify that the tissue has been fixed in 10% neutral buffered formalin for an optimal duration (typically 6 to 72 hours) to preserve antigenicity.
• No fasting or special dietary restrictions are required if you are only delivering a prepared tissue block or slide to the laboratory.

During the Procedure

The laboratory phase of CD-8 Immunohistochemistry at Lahore PCR Lab involves a series of highly controlled, automated steps performed by skilled histotechnologists and evaluated by consultant pathologists:

• Specimen Reception and Processing: The tissue specimen is fixed in formalin, processed through graded alcohols and xylene, and embedded in paraffin wax to create an FFPE block.
• Microtomy: Extremely thin sections (typically 3 to 5 microns) are cut from the paraffin block using a precision microtome and mounted onto charged glass slides to prevent tissue detachment during processing.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents to remove the paraffin wax, then rehydrated through descending grades of ethanol to water.
• Antigen Retrieval: Heat-Induced Epitope Retrieval (HIER) is performed using specialized buffer solutions to break the cross-links formed by formalin fixation, exposing the CD8 epitopes for antibody binding.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal antibody directed against the CD8 antigen.
• Detection and Visualization: A secondary detection system, typically utilizing a horseradish peroxidase (HRP) polymer, is applied, followed by a chromogen substrate such as 3,3′-diaminobenzidine (DAB). This produces a visible brown precipitate at the site of CD8 antigen expression.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cell nuclei (staining them blue), dehydrated, cleared, and sealed with a coverslip.
• Pathological Evaluation: A consultant pathologist examines the slides under a high-resolution light microscope to assess the staining pattern, intensity, and distribution of CD8+ cells.

When is a CD-8 Immunohistochemistry Test Performed?

1. Evaluation of Tumor-Infiltrating Lymphocytes (TILs)

Physicians frequently request CD-8 IHC to evaluate the immune microenvironment of solid tumors, including breast cancer, colorectal cancer, melanoma, and non-small cell lung cancer. The density and spatial organization of CD8+ cytotoxic T-cells within the tumor nest and stroma provide critical prognostic information, helping clinicians understand the host’s immune response against the malignancy.

2. Diagnosis of T-Cell Lymphomas

When a lymphoproliferative disorder is suspected, CD-8 IHC is essential for immunophenotyping. It helps pathologists differentiate between different subtypes of T-cell lymphomas, such as cytotoxic T-cell lymphoma, enteropathy-associated T-cell lymphoma, or mycosis fungoides, by confirming the expression or loss of the CD8 marker on neoplastic lymphocytes.

3. Assessment of Immunotherapy Eligibility

With the rise of personalized medicine, CD-8 IHC is increasingly used as a predictive biomarker. Patients with high levels of CD8+ T-cell infiltration in their tumors are often prime candidates for immune checkpoint inhibitors. Identifying these ‘immune-hot’ tumors helps oncologists tailor treatment plans, maximizing therapeutic efficacy while minimizing unnecessary side effects.

4. Monitoring Organ Transplant Rejection

In patients who have undergone solid organ transplantation (such as kidney, liver, or heart transplants), CD-8 IHC is performed on allograft biopsies to evaluate for acute cellular rejection. An influx of CD8+ cytotoxic T-cells into the graft tissue, such as the renal tubules or hepatic bile ducts, indicates an active, cell-mediated immune attack against the donor organ.

5. Investigation of Autoimmune and Inflammatory Disorders

CD-8 IHC assists in diagnosing and understanding various inflammatory dermatoses, neuromuscular disorders (like polymyositis), and autoimmune conditions. By identifying whether the inflammatory infiltrate is predominantly composed of CD8+ cytotoxic T-cells, pathologists can help clinicians distinguish between different autoimmune etiologies and guide targeted immunosuppressive therapy.

What Does a CD-8 Immunohistochemistry Test Detect?

CD-8 Immunohistochemistry detects several key pathological and immunological features within tissue specimens, including:

• Presence of CD8-positive cytotoxic T-lymphocytes in tissue sections.
• Intratumoral CD8+ lymphocyte density (cells within the tumor nests).
• Stromal CD8+ lymphocyte density (cells in the surrounding connective tissue).
• Invasive margin CD8+ T-cell distribution in solid tumors.
• Clonal expansion of CD8+ cells in suspected T-cell malignancies.
• Aberrant loss of CD8 expression in neoplastic T-cells.
• Co-expression patterns when compared with other markers like CD3, CD4, and CD56.
• CD8+ lymphocytic infiltration of renal tubules (tubulitis) in kidney transplant rejection.
• CD8+ lymphocytic infiltration of bile ducts (ductitis) in liver transplant rejection.
• Myocardial infiltration by CD8+ T-cells in suspected myocarditis or cardiac transplant rejection.
• Epidermotropism (infiltration of the epidermis by CD8+ T-cells) in cutaneous T-cell lymphomas.
• CD8+ T-cell mediated destruction of follicular epithelium in alopecia areata.
• Perivascular and endomysial CD8+ T-cell accumulation in polymyositis.
• Infiltration patterns in chronic viral infections (e.g., chronic hepatitis B or C in liver biopsies).
• Immune-excluded tumor patterns, where CD8+ cells are present but restricted to the stroma.
• Immune-desert tumor patterns, characterized by a complete absence of CD8+ T-cells.
• Activation state of CD8+ cells when combined with dual-staining markers like Granzyme B or Perforin.
• Infiltration of CD8+ T-cells in central nervous system biopsies in demyelinating diseases.
• Localization of CD8+ cells within mucosal biopsies of the gastrointestinal tract in inflammatory bowel disease.
• Distribution of CD8+ cells in lymphoid tissues (lymph nodes, spleen, tonsils) to assess reactive hyperplasia.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely results are crucial for clinical decision-making, particularly in oncology and transplant medicine. The turnaround time for CD-8 Immunohistochemistry typically ranges from 3 to 5 working days. This timeframe allows for meticulous tissue processing, automated staining, quality control validation, and comprehensive review by our consultant pathologists. Once the report is finalized, patients and referring physicians can access it securely online through the Lahore PCR Lab web portal or via our dedicated mobile application. Physical copies of the report can also be collected directly from our main diagnostic center in Lahore.

CD-8 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Tumor-Infiltrating Lymphocytes (TILs)	Low to moderate physiological presence in normal tissues.	High density (immune-hot tumor), stromal restriction (immune-excluded), or complete absence (immune-desert).
Lymph Node T-Zone	Abundant, well-distributed CD8+ T-cells in paracortical areas.	Depletion in immunodeficiency states; clonal expansion or atypical sheets in T-cell lymphoma.
Renal Allograft Biopsy	Minimal or absent CD8+ T-cells in interstitium and tubules.	Significant tubulitis and interstitial infiltration indicating acute cellular rejection.
Hepatic Portal Tracts	Sparse, resident CD8+ T-cells.	Dense CD8+ infiltration with interface hepatitis (chronic viral hepatitis or autoimmune hepatitis).
Skeletal Muscle Biopsy	No significant lymphocytic infiltrate.	Endomysial CD8+ T-cell infiltration surrounding healthy muscle fibers (polymyositis).
Skin Biopsy (Epidermis)	Very rare intraepidermal lymphocytes.	Marked epidermotropism of atypical CD8+ T-cells (cutaneous T-cell lymphoma).
Myocardial Biopsy	Absence of inflammatory cell infiltrates.	Focal or diffuse CD8+ T-cell infiltration associated with myocyte necrosis (myocarditis).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-8 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in histopathology and immunophenotyping.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate service throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring highly accurate and reproducible IHC staining.
• Professional Reporting: Our reports provide detailed, structured descriptions of CD8 staining patterns, offering clear diagnostic and prognostic insights for clinicians.
• Modern Diagnostic Approach: We utilize advanced automated staining systems that minimize human error and optimize antibody-antigen binding.
• Comfortable Environment: Our main facility in Lahore is designed to provide a welcoming, professional, and stress-free experience for patients submitting samples.
• Convenient Location: Strategically located in Lahore, our lab is easily accessible for patients, hospitals, and clinics across the region.
• Commitment to Accurate Diagnosis: We understand the critical impact of pathology results on cancer treatment and transplant management, maintaining an unwavering commitment to diagnostic precision.